As on Thursday, AbCellera Biologics Inc (NASDAQ: ABCL) started slowly as it slid -2.88% to $2.70, before settling in for the price of $2.78 at the close. Taking a more long-term approach, ABCL posted a 52-week range of $2.34-$6.05.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 387.52%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 10.68%. This publicly-traded company’s shares outstanding now amounts to $290.82 million, simultaneously with a float of $206.59 million. The organization now has a market capitalization sitting at $795.61 million. At the time of writing, stock’s 50-day Moving Average stood at $2.60, while the 200-day Moving Average is $3.70.
AbCellera Biologics Inc (ABCL) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. AbCellera Biologics Inc’s current insider ownership accounts for 29.89%, in contrast to 33.36% institutional ownership.
AbCellera Biologics Inc (ABCL) Earnings and Revenue Records
AbCellera Biologics Inc’s EPS increase for this current 12-month fiscal period is 10.68% and is forecasted to reach -0.56 in the upcoming year.
AbCellera Biologics Inc (NASDAQ: ABCL) Trading Performance Indicators
Let’s observe the current performance indicators for AbCellera Biologics Inc (ABCL). It’s Quick Ratio in the last reported quarter now stands at 10.96. The Stock has managed to achieve an average true range (ATR) of 0.14. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 24.07.
In the same vein, ABCL’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.53, a figure that is expected to reach -0.11 in the next quarter, and analysts are predicting that it will be -0.56 at the market close of one year from today.
Technical Analysis of AbCellera Biologics Inc (ABCL)
Through scrutinizing the latest numbers posted by the [AbCellera Biologics Inc, ABCL], it can be observed that its last 5-days Average volume of 2.16 million was better the volume of 1.61 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 70.28% While, its Average True Range was 0.14.
Raw Stochastic average of AbCellera Biologics Inc (ABCL) in the period of the previous 100 days is set at 23.40%, which indicates a major fall in contrast to 56.86% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 51.63% that was lower than 55.93% volatility it exhibited in the past 100-days period.
